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ABSTRACT 
Intracranial volume reflects the maximally attained brain size during development, and remains 
stable with loss of tissue in late life. It is highly heritable, but the underlying genes remain 
largely undetermined. In a genome-wide association study of 32,438 adults, we discovered five 
novel loci for intracranial volume and confirmed two known signals. Four of the loci are also 
associated with adult human stature, but these remained associated with intracranial volume 
after adjusting for height. We found a high genetic correlation with child head circumference 
(ρgenetic=0.748), which indicated a similar genetic background and allowed for the identification 
of four additional loci through meta-analysis (Ncombined = 37,345). Variants for intracranial 
volume were also related to childhood and adult cognitive function, Parkinson’s disease, and 
enriched near genes involved in growth pathways including PI3K-AKT signaling. These 
findings identify biological underpinnings of intracranial volume and provide genetic support 
for theories on brain reserve and brain overgrowth. 
The intricate genetic control of the human brain, complemented by environmental factors, leads to the 
observed variations in brain size in human populations1. Intracranial volume is closely related to brain 
volume in early life as the brain grows.2,3 However, it becomes stable after the brain has fully 
developed and remains unaffected by later age-related changes such as brain atrophy4,5, thus 
representing the maximal attained brain size. Discovering genetic variants that influence intracranial 
volume can contribute to our understanding of brain development and related diseases, but prior 
studies have only identified two influential genetic loci6-9.  
Here, we performed genome-wide association studies in populations from the Cohorts for Heart and 
Aging Research in Genomic Epidemiology (CHARGE)10 and Enhancing NeuroImaging Genetics 
through Meta-Analysis (ENIGMA)11 consortia on intracranial volume measured by magnetic 
resonance imaging. Genotypes were imputed to the 1000 Genomes reference panel (phase 1, version 
3). Meta-analysis revealed five novel loci associated with intracranial volume. We also discovered 
genome-wide overlap between intracranial volume and other key traits including height, cognitive 
ability, and Parkinson’s disease. Furthermore, we found relatively enriched patterns of association for 
certain functional categories of variants and near genes that are involved in specific pathways.   
RESULTS 
Genome-wide association studies 
Detailed information on the population characteristics, image acquisition and processing, and genetic 
quality control can be found in the Online Methods and Supplementary Tables S1-3. 
The discovery meta-analysis (N = 26,577) yielded seven genome-wide significant (p < 5 x 10-8) loci, 
five of them novel (Figures 1-2; Table 1). The quantile-quantile plot showed inflation (λ = 1.092; 
Supplementary Figure S1), which we determined to be mainly due to polygenicity rather than 
cryptic relatedness or population stratification using LD score regression12. Next we analyzed 
European samples (N = 2,362; not included in the discovery sample) and generalization samples with 
African (N = 938), Asian (N = 955), and Hispanic (N = 1,605) ancestries (Table 1). All variants had 
the same direction of effect in the additional European samples (sign test, P = 0.0078), and three 
variants replicated, at nominal significance. Although sample sizes were generally small for the non-
Europeans, here too, the direction of effect was generally concordant with the discovery (sign test, P = 
0.039). Five nominally significant associations were detected across all three ethnicities.  
Next we were able to map the association to novel variants for two previously identified loci at 
chromosome 17q21 (rs199525; P = 3.8 x 10-21) and 6q22 (rs11759026; P = 2.2 x 10-20)6,7. The five 
novel loci were on chr 6q21 (rs2022464; P = 3.7 x 10-11), chr 10q24 (rs11191683; P = 1.1 x 10-10), chr 
3q28 (rs9811910; P = 2.0 x 10-9), chr 12q14 (rs138074335/ rs7312464; P = 6.2 x 10-9), and chr 12q23 
(rs2195243; P = 1.5 x 10-8). Functional annotation of the variants and those in LD (r2 >0.8) can be 
found in Supplementary Table S4. 
Height-adjusted analyses 
Four of the seven loci for intracranial volume were previously discovered for height (17q21, 6q22, 
6q21, and 12q14), prompting us to investigate genome-wide overlap between the two traits. As height 
and intracranial volume are correlated (weighted average Pearson’s r = 0.556; Supplementary Table 
S5) and this could drive association signals, we performed a GWAS of intracranial volume adjusted 
for height in the studies that had measured height (N = 21,875). Findings were compared to the 
corresponding subset of studies without adjustment (N = 22,378). Using LD score regression (Online 
Methods), we found that there is considerable genetic correlation between intracranial volume and 
height (ρgenetic = 0.241, P = 2.4 x 10-10), which disappears after adjusting for height (ρgenetic = 0.049, P 
= 0.21) (Table 2). The associations of the seven intracranial volume loci, however, remained 
significant after adjusting for height (Supplementary Table S6). To investigate whether more height 
loci were associated with intracranial volume independently of height, we analyzed all 697 genome-
wide significant height variants13. An additional 73 variants (10.7%; 14 variants not available) showed 
nominally significant associations with intracranial volume but were not attenuated after adjustment 
for height, although none survived Bonferroni correction (Supplementary Table S7). For some 
variants, the direction of effect was discordant, i.e. positive for height and negative for intracranial 
volume. Furthermore, a polygenic score of the 697 variants predicted intracranial volume, and this 
was also the case after adjustment for height in a subset of the studies (Supplementary Table S8).  
Genetic correlation 
In addition to height, we examined the genome-wide genetic overlap between intracranial volume and 
other anthropometric traits, cognitive function, and neurodegenerative diseases (Table 2). We found a 
strong genetic correlation with child head circumference (ρgenetic = 0.748), which validates intracranial 
volume as a measure of brain growth during early development. Since this high correlation indicates 
that the genetic determinants of intracranial volume and child head circumference are largely shared, 
we aimed to leverage this information by performing a meta-analysis of both traits. The meta-analysis 
(combined N = 37,345) led to the identification of four novel loci (Figure 3; Supplementary Table 
S9). 
Weaker correlations were found with birth length and weight (ρgenetic < 0.3), which attenuated after 
adjusting for height. Additionally, intracranial volume was genetically correlated with cognitive 
function in childhood (ρgenetic = 0.277, P = 2.2x10-3) as well as general cognitive function in middle-
aged and older adults (ρgenetic = 0.202, P = 6.3x10-4). Furthermore, we found a positive genetic 
correlation with Parkinson’s disease (ρgenetic = 0.315, P = 6.6 x 10-7), but there was no significant 
genetic overlap with Alzheimer’s disease, white matter lesions, and psychiatric traits. 
Enrichment analyses 
Next, we assessed whether particular subsets of genetic variants were enriched for association with 
intracranial volume using partitioned heritability and pathway analyses (Online Methods). Overall, 
we found that common variants genotyped from across the whole genome explained 25.42% (S.E. 
2.73%) of the variation in intracranial volume. Partitioning heritability by chromosome showed that 
chromosome 22 contributed twofold more to variation in intracranial volume than would be expected 
by its size (Figure 4A), which was not seen for any of the other complex traits from the genetic 
correlation analysis (Supplementary Figure S2). Partitioning by functional elements showed an 
enrichment for introns and several histone codes that are found in actively transcribed promoters 
(Figure 4B). The enrichment for intronic variants was specific to intracranial volume, whereas the 
other functional classes were also enriched in other complex traits (Supplementary Figure S3).  We 
also found that loci associated with intracranial volume cluster around genes involved in specific 
pathways, with 94 pathways significantly enriched (Figure 4C; full list in Supplementary Table 
S10). These pathways included all cell cycle components – the M-, G1-, S-, and G2-phases – and 
various growth factor signaling pathways, including PI3K-AKT. 
Head growth trajectories 
Although intracranial volume reflects brain development until maturation, and we identified 
influences of many growth-related processes contributing to its variation, all loci were still discovered 
via cross-sectional associations in adults. Therefore, we tested whether a polygenic score of the 7 loci 
could predict head growth in a longitudinal cohort of 2,824 children of European ancestry followed 
prenatally until 6 years of age (Online Methods). We found that a higher polygenic score, 
representing a genetically larger intracranial volume in adults, was also associated with a larger child 
head circumference (β = .031 per SD, P = 0.010). Furthermore, the effect of the polygenic score was 
age-dependent and more prominent in older children (β = 0.0080 per SD polygenic score per year age, 
Pinteraction = 0.0091). When investigating the individual loci separately, both 17q21 and 12q14 showed 
significant associations with child head circumference, but they influenced the trajectories of head 
growth differently (Figure 4A-B). For 17q21, the negative impact of the G allele on head 
circumference becomes apparent postnatally and increases towards six years, whereas the 12q14 locus 
exerts an effect from early pregnancy to one year of age, but is less prominent later in life.  
DISCUSSION 
Genes contributing to variation in the size of the human brain remain challenging to discover. In a 
worldwide project of unprecedented scale, we performed the largest-ever meta-analysis of genome-
wide association studies of intracranial volume. We discovered five novel genetic loci associated with 
intracranial volume, and replicated two known signals. The discovery sample included Europeans 
only, but the direction of effect was similar in other ethnicities. The genes in these loci provide 
intriguing links between maximal brain size and various processes, including neural stem cell 
proliferation (FOXO3), neurodegeneration (MAPT), bone mineralization (CENPW), growth signaling 
(IGF1, HMGA2), DNA replication (GMNC), and rRNA maturation (PDCD). On a genome-wide 
scale, we discovered evidence of genetic correlation between intracranial volume and other key traits 
such as height and cognitive function, and also with Parkinson’s disease, indicating that the genes 
underlying brain development have far-reaching effects well beyond the initial years of life.  
The 17q21 locus tags a 1Mb inversion that is under positive selection in Caucasians14. It contains 
multiple genes including the MAPT and KANSL1. The MAPT gene is consistently implicated in 
various neurodegenerative disorders including Parkinson’s disease, Alzheimer’s disease, and 
frontotemporal dementia15,16, and microduplications have been reported to cause microcephaly17. 
KANSL1 causes the reciprocal 17q21.31 microdeletion syndrome - a multisystem disorder with 
intellectual disability, hypotonia and distinctive facial features18. The signal at 6q22 is intergenic to 
CENPW and RSPO3, but now lies 172kb closer to CENPW. Interestingly, multiple variants at this 
locus independently influence bone mineral density19,20, and our signal particularly overlaps with the 
variant showing high specificity for the skull20. 
The significant variants at chr 6q21 span FOXO3, a gene associated with longevity21, height13, and 
serum IGF1 levels22. FOXO3 regulates the proliferation of neural stem cells, and knockout mice show 
larger brains resulting from increased proliferation immediately after birth23, followed by a decrease 
in adult neural stem cell renewal23,24. The rs3800229 variant in strong LD with our top variant (r2 = 
0.84) contains chromatin promoter marks in the fetal brain (Supplementary Table S4), and regulates 
serum IGF1 levels in infants25. This provides a link to the genome-wide significant locus on chr12q23 
near IGF1, pointing to a potential mechanism through which these loci may affect brain growth. 
Chr12q23 lies 20Mb from one of two loci previously detected for head circumference in children26, 
but that region was not associated with intracranial volume in our study (rs7980687; P = 0.06). The 
other reported child head circumference locus, however, corresponded to our chr12q14 signal, with 
the top variant lying 14kb downstream of HMGA2, and already showed suggestive association with 
intracranial volume in a previous report7. It has also previously been associated with height13 and is 
essential for growth27. The chr10q24 LD-block covers multiple genes, but an intronic variant within 
PDCD11 is most significant. PDCD11 encodes an NF-kappa-B-binding protein required for rRNA 
maturation and generation of 18S rRNA28. A variant in LD (rs7894407) has recently been identified in 
a GWAS of cerebral white matter hyperintensities29. The top chr3q28 variant is located upstream of 
GMNC, which codes for the geminin coiled-coil domain-containing protein essential for DNA 
replication30. 
Prior efforts to identify variants affecting intracranial volume were much smaller and critically did not 
adjust for height6-9. We found that 4 out of 7 loci were already discovered for height13, but also that 
over 10% of the known ‘height loci’ actually affect intracranial volume, even after regressing out 
height. Interestingly, some variants showed discordant associations for height and intracranial volume 
- in line with the recent finding that different height loci disproportionally affect either leg length or 
spine/head length31 and may be a marker for pathological development32.  Also, height might thus 
serve as a proxy phenotype for intracranial volume, with the tenfold larger sample of the height 
GWAS giving greater power to detect associations. Neural genes are also enriched in pathway 
analyses of height13. However, to fully disentangle whether these identified genes are ‘height genes’, 
‘brain volume genes’, or ‘growth genes’ (i.e., pleiotropic), a large collaborative effort is needed that 
examines the association of these variants with both intracranial volume and height under various 
models. 
When investigating genome-wide overlap with other traits, we found a strong correlation with child 
head circumference, underlining that intracranial volume is valid measure for maximal attained brain 
size. We were able to leverage this genetic link by meta-analyzing both traits, which led to the 
identification of four additional loci (2q32.1, 3q23, 7p14.3, 22q13.2). The correlations with birth 
length and weight were weaker and decreased further after adjusting for height, so a similar 
phenotypic correlation between head size and body size at younger age may drive these correlations. 
Intracranial volume was also genetically associated with cognitive function in childhood as well as 
general cognitive function in middle-aged and older individuals. This indicates that variation in 
maximally attained brain size during development shares a genetic basis with cognitive ability later in 
life and supports intracranial volume as a measure of brain reserve5.  
The brain reserve hypothesis states that premorbid brain size can modify resilience to age-related 
brain pathology33, but there was no indication of a genome-wide overlap with Alzheimer’s disease. 
However, we found a positive genetic correlation with Parkinson’s disease that rather points to a brain 
“overgrowth” hypothesis. Interestingly, the IGF1 and the PI3K-AKT pathways, key factors in both 
growth signaling and our current study of intracranial volume, are neuroprotective in a model system 
of Parkinson’s disease34. There were no correlations with other neurological or psychiatric traits, 
indicating that this finding might be specific to Parkinson’s disease. However, it is important to note 
that there is a certain extent of variation in the sample size and power of these studies, and larger 
GWAS might reveal genetic correlation with other traits as well. 
It is not yet known if variance in intracranial volume, within the normal range, contributes to disease 
risk or brain reserve. There is no doubt that in the pathological extremes of the distribution, size can 
matter, as in disorders such as microcephaly or macrocephaly. Here we found evidence for a shared 
genetic background between intracranial volume and cognitive function, and risk of Parkinson’s 
disease. While not definitive, these are novel pieces of empirical evidence in the debate on whether or 
not whole brain size matters. 
The pathway analyses highlight cellular growth and proliferation and included all components of the 
cell cycle (M-, G1-, S-, and G2-phase) and various growth factor signaling pathways. PI3K-AKT 
signaling has a well described role in brain overgrowth disorders35,36, and was the only significant 
pathway using a different pathway analysis method (Supplementary Table S11). Interestingly, AKT3 
intronic variants showed suggestive evidence for association with intracranial volume (rs7538011; P = 
9.2 x 10-7). Deletions of AKT3 cause microcephaly syndromes37, whereas duplications give rise to 
macrocephaly38. Similar to FOXO3, it is part of the IGF1 signaling pathway, which is important for 
human longevity39. The PI3K-AKT signaling pathway seems to have an important role in brain 
growth, not only in pathological extremes, but also for normal variation at a population level. Other 
pathways enriched for association with intracranial volume highlight neuronal functions such as 
neurotransmission and axon guidance. 
We identified novel loci all influencing intracranial volume and, at a genome-wide level, there seem 
to be common pathways, but our longitudinal study reveals that their developmental effects are 
complex. The loci influenced trajectories of head growth differently; it also would be interesting to 
investigate whether their spatial profiles of effects are distinct, where certain loci promote growth of 
particular brain regions. 
Here we identified key genetic loci implicated in intracranial volume within a global collaborative 
effort, followed by computational analyses to determine the important biological pathways and 
functional elements. While the majority of the genetic variants are yet to be discovered, it is clear that 
these will provide better insight into brain development, but also into related neuropsychiatric traits 
such as cognitive functioning and even for neurodegeneration late in life. Uncovering the remaining 
heritability will advance our understanding of the brain’s complex genetic architecture. 
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Published GWASs used for genetic correlation analysis 
CHARGE consortium: See Davies et al.47 for the general cognitive function GWAS, and Verhaaren 
et al.50  for the white matter lesion GWAS. 
Early Growth Genetics (EGG) consortium: Data on head circumference, birth weight, and birth 
length have been contributed by the EGG Consortium and has been downloaded from www.egg-
consortium.org. 
Genetic Investigation of ANthropometric Traits (GIANT) consortium: See Wood et al.13 
Genetics of Personality Consortium: See De Moor et al.52 for the neuroticism GWAS and Van den 
Berg et al.53 for the extraversion GWAS. 
IGAP: We thank the International Genomics of Alzheimer's Project (IGAP) for providing summary 
results data for these analyses. The investigators within IGAP contributed to the design and 
implementation of IGAP and/or provided data but did not participate in analysis or writing of this 
report. IGAP was made possible by the generous participation of the control subjects, the patients, and 
their families. The i–Select chips was funded by the French National Foundation on Alzheimer's 
disease and related disorders. EADI was supported by the LABEX (laboratory of excellence program 
investment for the future) DISTALZ grant, Inserm, Institut Pasteur de Lille, Université de Lille 2 and 
the Lille University Hospital. GERAD was supported by the Medical Research Council (Grant n° 
503480), Alzheimer's Research UK (Grant n° 503176), the Wellcome Trust (Grant n° 082604/2/07/Z) 
and German Federal Ministry of Education and Research (BMBF): Competence Network Dementia 
(CND) grant n° 01GI0102, 01GI0711, 01GI0420. CHARGE was partly supported by the NIH/NIA 
grant R01 AG033193 and the NIA AG081220 and AGES contract N01–AG–12100, the NHLBI grant 
R01 HL105756, the Icelandic Heart Association, and the Erasmus Medical Center and Erasmus 
University. ADGC was supported by the NIH/NIA grants: U01 AG032984, U24 AG021886, U01 
AG016976, and the Alzheimer's Association grant ADGC–10–196728. 
International Parkinson's Disease Genomics Consortium (IPDGC): See Nalls et al.49 
Psychiatric Genomics Consortium: See Cross-Disorder Group of the Psychiatric Genomics paper. 51 
Social Science Genetic Association Consortium (SSGAC): See Benyamin et al.46 for the childhood 
cognitive function GWAS. 
 
 
COMPETING FINANCIAL INTERESTS STATEMENT  
The authors declare no competing financial interest related to any of the work described in this 
manuscript.  
  
REFERENCES 
1 Bartley, A. J., Jones, D. W. & Weinberger, D. R. Genetic variability of human brain size and 
cortical gyral patterns. Brain 120, 257-269 (1997). 
2 Davis, P. J. M. & Wright, E. A. A new method for measuring cranial cavity volume and its 
application to the assessment of cerebral atrophy at autopsy. Neuropathology and applied 
neurobiology 3, 341-358 (1977). 
3 Sgouros, S., Goldin, J. H., Hockley, A. D., Wake, M. J. & Natarajan, K. Intracranial volume 
change in childhood. Journal of neurosurgery 91, 610-616 (1999). 
4 Buckner, R. L. et al. A unified approach for morphometric and functional data analysis in 
young, old, and demented adults using automated atlas-based head size normalization: 
reliability and validation against manual measurement of total intracranial volume. 
Neuroimage 23, 724-738 (2004). 
5 Farias, S. T. et al. Maximal brain size remains an important predictor of cognition in old age, 
independent of current brain pathology. Neurobiology of aging 33, 1758-1768 (2012). 
6 Ikram, M. A. et al. Common variants at 6q22 and 17q21 are associated with intracranial 
volume. Nat Genet 44, 539-544, doi:10.1038/ng.2245 (2012). 
7 Stein, J. L. et al. Identification of common variants associated with human hippocampal and 
intracranial volumes. Nat Genet 44, 552-561, doi:10.1038/ng.2250 (2012). 
8 Hibar, D. P. et al. Common genetic variants influence human subcortical brain structures. 
Nature, doi:10.1038/nature14101 (2015). 
9 Paus, T. et al. KCTD8 gene and brain growth in adverse intrauterine environment: a genome-
wide association study. Cerebral Cortex 22, 2634-2642 (2012). 
10 Psaty, B. M. et al. Cohorts for Heart and Aging Research in Genomic Epidemiology 
(CHARGE) consortium design of prospective meta-analyses of genome-wide association 
studies from 5 cohorts. Circulation: Cardiovascular Genetics 2, 73-80 (2009). 
11 Thompson, P. M. et al. The ENIGMA Consortium: large-scale collaborative analyses of 
neuroimaging and genetic data. Brain imaging and behavior 8, 153-182 (2014). 
12 Bulik-Sullivan, B. K. et al. LD Score regression distinguishes confounding from polygenicity 
in genome-wide association studies. Nat Genet 47, 291-295, doi:10.1038/ng.3211 (2015). 
13 Wood, A. R. et al. Defining the role of common variation in the genomic and biological 
architecture of adult human height. Nat Genet 46, 1173-1186, doi:10.1038/ng.3097 (2014). 
14 Stefansson, H. et al. A common inversion under selection in Europeans. Nature genetics 37, 
129-137 (2005). 
15 Spillantini, M. G. & Goedert, M. Tau pathology and neurodegeneration. The Lancet 
Neurology 12, 609-622 (2013). 
16 Desikan, R. et al. Genetic overlap between Alzheimer’s disease and Parkinson’s disease at the 
MAPT locus. Molecular psychiatry (2015). 
17 Kirchhoff, M., Bisgaard, A. M., Duno, M., Hansen, F. J. & Schwartz, M. A 17q21.31 
microduplication, reciprocal to the newly described 17q21.31 microdeletion, in a girl with 
severe psychomotor developmental delay and dysmorphic craniofacial features. European 
journal of medical genetics 50, 256-263, doi:10.1016/j.ejmg.2007.05.001 (2007). 
18 Koolen, D. A. et al. Mutations in the chromatin modifier gene KANSL1 cause the 17q21. 31 
microdeletion syndrome. Nature genetics 44, 639-641 (2012). 
19 Estrada, K. et al. Genome-wide meta-analysis identifies 56 bone mineral density loci and 
reveals 14 loci associated with risk of fracture. Nature genetics 44, 491-501 (2012). 
20 Kemp, J. P. et al. Phenotypic dissection of bone mineral density reveals skeletal site 
specificity and facilitates the identification of novel loci in the genetic regulation of bone 
mass attainment. PLoS genetics 10, e1004423 (2014). 
21 Broer, L. et al. GWAS of Longevity in CHARGE Consortium Confirms APOE and FOXO3 
Candidacy. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 
70, 110-118 (2015). 
22 Kaplan, R. C. et al. A genome-wide association study identifies novel loci associated with 
circulating IGF-I and IGFBP-3. Human molecular genetics 20, 1241-1251 (2011). 
23 Paik, J.-h. et al. FoxOs cooperatively regulate diverse pathways governing neural stem cell 
homeostasis. Cell stem cell 5, 540-553 (2009). 
24 Renault, V. M. et al. FoxO3 regulates neural stem cell homeostasis. Cell stem cell 5, 527-539 
(2009). 
25 Rzehak, P. et al. Associations of IGF-1 gene variants and milk protein intake with IGF-I 
concentrations in infants at age 6months—Results from a randomized clinical trial. Growth 
hormone & IGF research 23, 149-158 (2013). 
26 Taal, H. R. et al. Common variants at 12q15 and 12q24 are associated with infant head 
circumference. Nat Genet 44, 532-538, doi:10.1038/ng.2238 (2012). 
27 Lynch, S. A. et al. The 12q14 microdeletion syndrome: six new cases confirming the role of 
HMGA2 in growth. European Journal of Human Genetics 19, 534-539 (2011). 
28 Sweet, T., Yen, W., Khalili, K. & Amini, S. Evidence for involvement of NFBP in processing 
of ribosomal RNA. Journal of cellular physiology 214, 381-388 (2008). 
29 Verhaaren, B. F. et al. Multi-Ethnic Genome-Wide Association Study of Cerebral White 
Matter Hyperintensities on MRI. Circulation: Cardiovascular Genetics, CIRCGENETICS. 
114.000858 (2015). 
30 Balestrini, A., Cosentino, C., Errico, A., Garner, E. & Costanzo, V. GEMC1 is a TopBP1-
interacting protein required for chromosomal DNA replication. Nature cell biology 12, 484-
491 (2010). 
31 Chan, Y. et al. Genome-wide Analysis of Body Proportion Classifies Height-Associated 
Variants by Mechanism of Action and Implicates Genes Important for Skeletal Development. 
The American Journal of Human Genetics (2015). 
32 Fukumoto, A. et al. Head circumference and body growth in autism spectrum disorders. Brain 
and Development 33, 569-575 (2011). 
33 Stern, Y. Cognitive reserve in ageing and Alzheimer's disease. The Lancet Neurology 11, 
1006-1012 (2012). 
34 Quesada, A., Lee, B. Y. & Micevych, P. E. PI3 kinase/Akt activation mediates estrogen and 
IGF‐1 nigral DA neuronal neuroprotection against a unilateral rat model of Parkinson's 
disease. Developmental neurobiology 68, 632-644 (2008). 
35 Hevner, R. F. in Seminars in perinatology.  36-43 (Elsevier). 
36 Rivière, J.-B. et al. De novo germline and postzygotic mutations in AKT3, PIK3R2 and 
PIK3CA cause a spectrum of related megalencephaly syndromes. Nature genetics 44, 934-
940 (2012). 
37 Boland, E. et al. Mapping of deletion and translocation breakpoints in 1q44 implicates the 
serine/threonine kinase AKT3 in postnatal microcephaly and agenesis of the corpus callosum. 
The American Journal of Human Genetics 81, 292-303 (2007). 
38 Wang, D., Zeesman, S., Tarnopolsky, M. A. & Nowaczyk, M. J. Duplication of AKT3 as a 
cause of macrocephaly in duplication 1q43q44. American Journal of Medical Genetics Part A 
161, 2016-2019 (2013). 
39 Pawlikowska, L. et al. Association of common genetic variation in the insulin/IGF1 signaling 
pathway with human longevity. Aging cell 8, 460-472 (2009). 
 
FIGURE LEGENDS 
Figure 1. Common genetic variants associated with intracranial volume. 
Manhattan plot where every point represents a single genetic variant plotted according to its genomic 
position (x-axis) and its –log10(p-value) for association with intracranial volume (y-axis). Variants in 
blue are genome-wide significant in a previously known locus, whereas red variants reach genome-
wide significant for the first time in that locus. The dashed horizontal line represents a significance 
threshold of p-value < 10-6 and the full horizontal line represents genome-wide significance of p-value 
< 5 x 10-8. Variants surpassing these thresholds are indicated by larger points. 
Figure 2. Regional association and functional annotation of novel genome-wide significant loci. 
Regional association plots for the five novel genome-wide significant loci of intracranial volume with 
gene models below (GENCODE version 19). Annotation tracks below from the Roadmap 
Epigenomics Consortium57 highlight the genomic region that likely harbors the causal variant(s) (r2 > 
0.8 from the top SNP). See Online Methods for detailed track information. Plots were generated 
using the LocusTrack software (http://gump.qimr.edu.au/general/gabrieC/LocusTrack/). 
Figure 3. Meta-analysis of intracranial volume and child head circumference. 
A ‘twin’ Manhattan plot shows every variant twice: once for the discovery analysis and once for the 
combined discovery plus replication analysis. The least significant association of the variant-pair is 
plotted in grey (alternating light and dark between chromosomes). The most significant association of 
the variant-pair is plotted in red if is from the combined analysis (i.e., the association became more 
significant after meta-analyzing with the child head circumference GWAS) and in turquoise if it is 
from the discovery analysis (i.e., the association became less significant after meta-analyzing with the 
child head circumference GWAS). The dashed horizontal line represents a significance threshold of p-
value < 10-6 and the full horizontal line represents genome-wide significance of p-value < 5 x 10-8. 
Variants surpassing these thresholds are indicated by larger and brighter points. 
Figure 4. Enrichment analyses of common variants associated with intracranial volume. 
Enrichment of subsets of variants for association with intracranial volume: A) by chromosomes, B) by 
functional subtype, and C) by pathway. See Online Methods for additional information. 
Figure 5. Temporal trends of intracranial volume loci during pre- and postnatal brain 
development. 
Mean predicted values of standardized head circumference using linear mixed models with age, sex, 
and the rs199525 or rs138074335 variants. The blue line represents children not carrying the risk 
allele, purple only a single risk allele, and red with two risk alleles. See Online Methods for 
additional information. Total sample size is 2,824. 
TABLES 
Table 1. Association of genome-wide significant loci for intracranial volume in European, African, Asian, and Hispanic populations. 
      
European 
discovery  
(N=26,577) 
European 
replication  
(N=2,363) 
African 
generalization 
(N=938) 
Asian 
generalization 
(N=955) 
Hispanic 
generalization 
(N=1605) 
Genetic variant Locus Position A1 A2 Freq β P β P β P β P β P 
                
rs199525 17q21 44847834 T G 0.80 .102 3.8x10-21 .024 0.407 .358 1.3x10-3 .264 0.406 .035 0.493 
rs11759026 6q22 126792095 A G 0.76 -.095 2.2x10-20 -.019 0.528 -.131 0.194 -.071 0.123 -.046 0.209 
rs2022464 6q21 108945370 A C 0.30 -.063 3.7x10-11 -.090 4.7x10-3 -.060 0.233 -.105 0.035 -.088 0.013 
rs11191683 10q24 105170649 T G 0.33 .059 1.1x10-10 .040 0.174 .187 0.021 .085 0.075 -.005 0.911 
rs9811910 3q28 190670902 C G 0.08 .096 1.2x10-9 .075 0.010 .346 0.020 .101 0.621 -.148 0.187 
rs138074335 12q14 66374247 A G 0.59 .051 6.2x10-9 .106 2.9x10-4 -.016 0.735 -.004 0.951 .001 0.984 
rs2195243 12q23 102922986 C G 0.22 -.059 1.5x10-8 -.044 0.132 .037 0.585 -.020 0.774 -.093 0.101 
 
Abbreviations: A1 = effect allele, A2 = reference allele, Freq = frequency of the effect allele, SE = standard error, N = sample size. 
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Table 2. Genetic correlation between intracranial volume and other anthropometric traits, cognitive function, and neurodegenerative diseases. 
   Intracranial volume 
Full sample (N=26,577) 
Intracranial volume 
Height subset (N=22,378) 
Intracranial volume 
Height adjusted (N=21,875) 
Phenotype N total N cases ρgenetic SE P ρgenetic SE P ρgenetic SE P 
            
Anthropometric traits            
Adult height 253,280 - .249 .037 1.4x10-11 .241 .038 2.4x10-10 .049 .039 0.21 
Child head circumference 10,768 - .748 .121 5.5x10-10 .758 .124 1.1x10-9 .750 .126 2.5x10-9 
Birth length 28,459 - .296 .087 6.7x10-4 .278 .087 1.3x10-3 .192 .088 0.029 
Birth weight 26,836 - .285 .081 4.4x10-4 .219 .082 7.9x10-3 .160 .086 0.062 
Neurological traits            
Childhood cognitive function 12,441 - .277 .090 2.2x10-3 .277 .091 2.5x10-3 .257 .090 4.2x10-3 
Adult cognitive function 53,949 - .202 .059 6.3x10-4 .205 .060 6.0x10-4 .198 .059 6.9x10-4 
Alzheimer's Disease 54,162 17,008 -.070 .097 0.47 -.049 .097 0.61 -.043 .098 0.66 
Parkinson's Disease 108,990 13,708 .315 .063 6.6x10-7 .316 .070 5.5x10-6 .335 .072 3.0x10-6 
White matter lesions 17,936 - .112 .075 0.13 .111 .078 0.16 .096 .079 0.23 
Psychiatric traits            
Autism 10,263 4,949 -.011 .069 0.87 -.036 .074 0.63 .026 .071 0.72 
Bipolar disorder 11,810 6,990 .070 .071 0.33 .007 .075 0.93 -.004 .076 0.95 
Major depressive disorder 16,610 9,227 .002 .100 0.98 .025 .098 0.80 .005 .096 0.96 
Schizophrenia 17,115 9,379 .054 .056 0.33 .017 .058 0.77 -.009 .058 0.87 
Extraversion 63,030 - -.041 .092 0.65 -.101 .095 0.29 -.097 .092 0.29 
Neuroticism 63,661 - -.017 .109 0.87 .035 .106 0.74 .070 .111 0.53 
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Genetic correlation between various phenotypes and intracranial volume in the complete discovery sample (“Full sample”), adjusted for height in 
the studies that had measured height (“Height adjusted”), and the corresponding subset of studies without adjustment (“Height subset”).  
Abbreviations: SE = standard error. 
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ONLINE METHODS 
Study population 
This study reports data on 32,438 subjects from 52 study sites that are part of the Cohorts for Heart 
and Aging Research in Genomic Epidemiology (CHARGE)10 consortium and Enhancing 
NeuroImaging Genetics through Meta-Analysis (ENIGMA)11 consortium. Briefly, the CHARGE 
consortium is a collaboration of predominantly population-based cohort studies that investigate the 
genetic and molecular underpinnings of age-related complex diseases, including those of the brain. 
The ENIGMA consortium brings together numerous studies, mainly with a case-control design, which 
performed neuroimaging in a range of neuropsychiatric or neurodegenerative diseases, as well as 
healthy normative populations. Studies participated in either the discovery cohort of European 
ancestry, the replication in European ancestry, or the generalization to other ethnicities. An overview 
of the demographics and type of contribution for each cohort is provided in Supplementary Table 
S1. Written informed consent was obtained from all participants. Each study was approved by the 
respective Institutional Review Board or Local Ethics Committee. 
Genetics 
Genotyping was performed using a variety of commercial arrays across the contributing sites. Both 
samples as well as variants underwent similar quality control procedures based on genetic 
homogeneity, call rate (less than 95%), minor allele frequency (MAF < 0.01), and Hardy-Weinberg 
Equilibrium (HWE p-value less than 1 x 10-6). Good quality variants were used as input for 
imputation to the 1000 Genomes reference panel (phase 1, version 3) using validated software 
packages (MaCH/minimac, IMPUTE2, BEAGLE, GenABLE). Variants that were poorly imputed 
(R2 < 0.5) or uncommon (MAF < 0.5%) were removed prior to meta-analysis. Full details on the site-
specific genotyping and quality control may be found in Supplementary Table S2.  
Imaging 
Magnetic resonance imaging (MRI) was obtained from scanners with a diversity of manufacturers, 
field strengths, and acquisition protocols. Images were used to estimate milliliters of intracranial 
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volume from automated segmentations generated by freely available or in-house methods that have 
been described and validated earlier. Most sites measured intracranial volume for each participant by 
multiplying the inverse of the determinant of the transformation matrix required to register the 
subject’s MRI scan to a common template by the template volume (1,948,105 mm3), using the 
FreeSurfer software. Visual inspections were performed to identify and remove poorly segmented 
images. Either all scans were visually inspected, or sites generated histogram plots to identify any 
outliers, which were defined as individuals with a volume more than three standard deviations away 
from the mean. Statistical outliers were only excluded if the segmentations were deemed improper. . 
More site-specific information related to the imaging is available in Supplementary Table S3.  
Genome-wide association studies 
Genome-wide association studies of intracranial volume were performed for each site separately, 
controlling for age, sex, and, when applicable, age2, population stratification variables (MDS / 
principal components), study site (for multi-site studies only), diagnosis (for case-control studies 
only). Studies of unrelated individuals performed a linear regression analyses whereas studies of 
related individuals (ASPSFam, BrainSCALE, ERF, GeneSTAR, GOBS, NeuroIMAGE, NTR-Adults, 
OATS, QTIM, SYS) used linear mixed models to account for familial relationships. Summary 
statistics, including the effect estimates of the genetic variant with intracranial volume under an 
additive model, were exchanged to perform a fixed-effects meta-analysis weighting for sample size in 
METAL40. After the final meta-analysis, variants were excluded if they were only available for fewer 
than 5,000 individuals.  Meta-analyses were stratified by race and done separately for discovery, 
replication, and generalization samples. Beta coefficients were recalculated from Z-scores, allele 
frequencies, and the sample, as described earlier41  Site-specific quantile-quantile plots were generated 
to inspect the presence of genomic inflation. The variance explained by all variants in the GWAS was 
estimated using LD score regression12,42. Sensitivity analyses were performed by excluding patients. 
Functional annotation 
All tracks of the regional association plots were taken from the UCSC Genome Browser Human hg19 
assembly. SNPs (top 5%) shows the top 5% associated variants within the locus and are colored by 
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their correlation to the top variant. Genes shows the gene models from GENCODE version 19. The 
tracks give the predicted chromatin states based on computational integration of ChIP-seq data for 12 
chromatin marks in various human tissues derived from the Roadmap Epigenomics Consortium43. 
Additionally, we used HaploReg version 3 for annotation of the top variants and all variants in LD (> 
0.80) (http://www.broadinstitute.org/mammals/haploreg/haploreg_v3.php).  
Genetic correlation 
The genetic correlation analyses were also performed using LD score regression. The GWAS meta-
analysis of intracranial volume, as well as the height adjusted and height subset meta-analyses, were 
correlated with published GWAS  of the following traits: Child head circumference26, birth weight44, 
birth length45, adult height13, childhood cognitive function46, adult cognitive function47, Alzheimer’s 
disease48, Parkinson’s disease49, white matter lesions50, psychiatric disorders51,  neuroticism52, and 
extraversion53. 
Enrichment analyses 
To determine whether the intracranial volume association results were enriched for certain types of 
genetic variants, we employed two strategies: partitioned heritability and pathway analyses.  
Partitioned heritability was calculated using a previously described method42. This was done by 
partitioning variants by chromosome and by 28 functional classes: coding, UTR, promoter, intron, 
histone marks H3K4me1, H3K4me3, H3K9ac5 and two versions of H3K27ac, open chromatin DNase 
I hypersensitivity Site (DHS) regions, combined chromHMM/Segway predictions, regions that are 
conserved in mammals, super-enhancers and active enhancers from the FANTOM5 panel of samples 
(Finucane et al. page 4)42. Multiple testing thresholds were calculated accordingly: Pthresh = 0.05/(22 
chromosomes) = 2.27 x 10-3  for the chromosomes and Pthresh = 0.05/(28 classes) = 1.79 x 10-3 for the 
functional classes. 
Pathway analyses were performed using the KGG2.554 and MAGENTA55 software packages. LD was 
calculated based with the 1000 Genomes Project European samples as a reference (see URLs). 
Variants were considered to be within a gene if they were within 5 kb of the 3’/5’ UTR based on 
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chromosome positions (hg19) coordinates. Gene-based tests were done with the GATES test54 without 
weighting P-values by predicted functional relevance. Pathway analysis was performed using the 
HYST test of association56. A multiple testing threshold accounting for the number of pathways tested 
resulting in a significance threshold of Pthresh = 0.05/(671 pathways) = 7.45 x 10-5.   
Head growth trajectories 
Head growth trajectory analyses were done within the Generation R study, a longitudinal cohort study 
situated in Rotterdam, the Netherlands. For this analysis we included 2,824 children of European 
ancestry followed prenatally until 6 years of age. Head size was measured at the following points: 
prenatally (using echo) during the first, second, and third trimester, and postnatally (measuring head 
circumference) at 0-2 months, 2 months, 3 months, 4 months, 5-10 months, 10-13 months, 13-17 
months, and 5 years of age. We tested whether a polygenic score of the 7 loci, as well as the 7 loci 
themselves separately, were related to head growth  using linear mixed models and included an 
interaction term between time and the genetic score/variant (SAS software). Next, the predicted 
values were calculated for each person and plotted over time, stratified by genotype (0/1/2 risk alleles) 
using the R software package.   
URLs 
ftp://pricelab:pricelab@ftp.broadinstitute.org/LDSCORE/ 
http://enigma.ini.usc.edu/protocols/genetics-protocols/ 
http://genenetwork.nl/bloodeqtlbrowser/ 
http://gump.qimr.edu.au/general/gabrieC/LocusTrack/). 
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